A b s t r a c t
Cytomegalovirus (CMV) is a 230-kb member of the herpesvirus family that can infect a wide variety of host tissues. Although about 50% of the US population has been exposed to CMV by early adulthood, 1 severe clinical illness is mostly limited to immunocompromised people, including fetuses, neonates, HIV-infected people, and transplant recipients. Recognizing and responding to primary infection or reactivation early in the course of the illness is key to limiting CMV disease severity. 2 Serology, viral culture, antigen detection, and viral nucleic acid detection have all been used for diagnosis and monitoring of at-risk immunocompromised patients for active CMV infection. Nucleic acid methods have the advantages of high sensitivity, rapid time to results, and ability to provide quantitative viral load measurements and have become the assays of choice for most applications. 3 However, no current US Food and Drug Administration-approved test for CMV viremia exists, and universal reference standards that would allow for result harmonization among the various test methods are not available. 4 Each laboratory, therefore, aims to provide precise and reproducible viral load results with the expectation that clinicians will be monitoring their patients at the same laboratory over time, because results from different laboratories cannot be readily compared.
Nucleic acid extraction methods have a major impact on polymerase chain reaction (PCR) test performance. Most clinical laboratories are moving toward automated technologies, and there are a variety of instruments available with varying capacity and specimen handling protocols. Most of these rely on silica binding to DNA/RNA for removal of nonnucleic acid components. For applications requiring high sensitivity, such as viral detection in clinical samples, extracted nucleic acid cannot be measured directly postextraction but must be Upon completion of this activity you will be able to:
• describe the various components of clinical assay systems for cytomegalovirus (CMV) viral load testing.
• compare the relative bias due to changes in nucleic acid extraction methods and understand the effect on clinical results interpretation.
• discuss how improved sensitivity for CMV detection by PCR can affect patient management.
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coupled to an amplification or detection system such as realtime PCR. Therefore, there are a large number of variables to be considered when evaluating these systems, including sample type(s) used, virus(es) of interest, extraction technology, fluidics automation, throughput, concentration factor, run time, ease of use, and cost. A recent study showed some extraction methods having 10-to 100-fold reduced sensitivity in virus detection when analyzed by real-time PCR at a single center. 5 We performed this study to evaluate 2 automated nucleic extraction instruments, the QIAGEN BioRobot EZ1, a small bench-top batch processor, and the QIAGEN QIAsymphony SP (QIAGEN, Valencia, CA), a recently available nucleic acid extractor with high throughput capacity. We performed real-time quantitative PCR for CMV on human plasma samples and cultured virus material and compared PCR results with the CMV pp65 antigenemia assay. This is the first report we are aware of that describes use of the QIAsymphony SP extractor for a clinical assay.
Materials and Methods

Specimens
Excess specimen was used from plasma collected for CMV analysis by antigenemia or PCR methods in accordance with institutional review board-approved protocols. Samples from adult and pediatric hematopoietic stem cell or solid organ transplant recipients were included. Samples were taken for routine outpatient monitoring or inpatient diagnostic workup and subsequent monitoring for CMV disease.
Cultured CMV was prepared from American Type Culture Collection stock (VR-538) by growing the cells in human foreskin fibroblast (Diagnostic Hybrids, Athens, OH) or SF human fibroblast (ViroMed Laboratories, Minnetonka, MN) cell lines using RM-02 (refeed medium 2% serum) at 36°C until cell death. Cell culture supernatant, termed CMV AD-169, containing viral particles was removed and stored at -70°C until used in viral load assays.
Nucleic Acid Extraction
BioRobot EZ1 extractions were performed using 400 μL of plasma with an elution volume of 90 μL (concentration factor, 4.44) using the EZ1 Virus 2.0 Kit (QIAGEN). QIAsymphony SP extractions were performed using 1,000 μL of plasma with an elution volume of 85 μL (concentration factor, 11.76) using the QIAsymphony Virus/Bacteria Midi Kit (QIAGEN). An internal control plasmid (Roche CMV UL54 Recovery Template, Roche Diagnostics, Indianapolis, IN) was added to each sample before extraction. All results were corrected by the extraction concentration factor to yield the quantity of virus present in the original plasma specimen in log 10 copies/mL.
Real-Time PCR
Real-time PCR was performed using CMV analyte-specific reagents (Roche) targeting the UL54 DNA polymerase gene, as previously described, 6 with the following modifications: uracil-DNA glycosylase (Roche) was added at 0.25 μL per 20 μL reaction, and samples were held at 40°C for 10 minutes to degrade uracil-containing DNA before PCR amplification. Each run contained a single standard whose value was used to anchor the assay standard curve determined in a separate run. The ƒ'' maximum, or "second derivative maximum," method was used to determine the amplification result. Runs were considered valid if a negative control yielded no amplification and the low-positive and high-positive control values were within 2 SD of the expected mean. Samples without amplification were considered to be true negatives only if the internal control amplified within 3 SD of the mean value. All instrument-determined values were reviewed and adjusted, if necessary, by manual review of the data plots. Amplification was performed on the LightCycler 2.0 instrument (Roche), and results were analyzed with Roche software, version 4.05.
CMV Antigenemia Assay
CMV antigenemia testing was performed using EDTA whole blood following the test procedure described in the package insert of the CMV Brite Turbo kit (IQ Products, Groningen, Netherlands). Cytocentrifuged preparations (Cytospin 3, Shandon Scientific, Cheshire, England) of a known quantity of peripheral blood leukocytes (200,000 cells) were stained using indirect immunofluorescence with a cocktail of 2 fluorescein isothiocyanate-labeled monoclonal antibodies (C10/C11) directed against CMV lower matrix protein pp65. The slides were immediately read using a fluorescence microscope looking for leukocytes exhibiting homogeneous bright green polylobate nuclear staining. The CMV antigenpositive cells were counted and reported per 200,000 WBCs.
Study Design
Linearity was assessed by using CMV AD-169 viral supernatant serially diluted with normal human plasma that did not contain detectable CMV DNA. Dilutions were assessed in duplicate and results averaged. Results were considered linear when the R 2 value was more than 0.99 and actual results were within 0.3 log 10 copies/mL of the expected value. The limit of detection was determined by using serially diluted CMV AD-169 in duplicate during the course of 3 separate runs and was defined as the lowest dilution having more than a 95% detection rate. Precision was determined by using 2 levels of CMV AD-169 tested in duplicate during 10 days for a total of 20 data points for each level. Agreement between the 2 extraction methods was determined by using 29 patient plasma samples extracted by both methods and amplified during the same run, with the overall bias for samples positive in both methods determined by using difference plot analysis (Bland-Altman). 7 Comparison with CMV antigenemia was made by using whole blood patient samples that were split and analyzed for antigenemia or centrifuged with plasma extracted and CMV DNA amplified by PCR. Limited sample volume precluded simultaneous analysis of some specimens by CMV antigenemia and both extraction methods.
Results
Extraction Time and Sample Throughput
The BioRobot EZ1 has a capacity of 6 samples, whereas the QIAsymphony SP accepts up to 4 racks containing 24 samples each. Each run on the EZ1 takes approximately 30 minutes to set up and 45 minutes of run time on the instrument. The QIAsymphony takes approximately 2.5 hours to set up and has a run time of 1 hour and 20 minutes.
Linearity and Limit of Detection
Both extraction methods were linear for approximately 4 orders of magnitude, up to the upper limit tested. With a criterion of being within 0.3 log 10 units of expected values, the BioRobot EZ1 had a linear range of 6.76 to 2.86 log 10 copies/mL. The QIAsymphony SP had a linear range of 6.95 to 2.83 log 10 copies/mL ❚Figure 1❚. EZ1 extracted material was detected in at least 95% of samples down to a level of 2.26 log 10 copies/mL, while the QIAsymphony-extracted material was detected to a level of 1.92 log 10 copies/mL.
Precision
Control samples processed with BioRobot EZ1 extraction had a coefficient of variation of 4.0% for low-level control material with 3.70 log 10 copies/mL and 1.6% for high-level control material with 6.15 log 10 copies/mL. Control samples processed with QIAsymphony had a coefficient of variation of 3.7% for low-level control material with 3.86 log 10 copies/ mL and 1.6% for high-level control material with 6.44 log 10 copies/mL.
Agreement
Of 29 samples tested by both EZ1 and QIAsymphony extractions, 18 were positive by both methods. Four samples were positive after QIAsymphony extraction at 2.59, 2.88, 2.97, and 3.60 log 10 copies/mL that were not detected after EZ1 extraction. No samples that were detected after EZ1 extraction were negative with QIAsymphony extraction. The average difference between the 2 extraction methods was 0.08 log 10 copies/mL, with the EZ1 extracted material yielding results that were 62% higher on average when expressed in copies/mL of virus particles. This positive bias was present primarily for samples with average viral loads of less than 4.0 log 10 copies/mL, whereas samples with viral loads greater than 4.0 log 10 copies/mL showed a slight negative bias ❚Figure 2❚. ❚Figure 2❚ Difference plot of 18 matched patient samples positive for cytomegalovirus viremia using EZ1 and QIAsymphony extracted material. The dotted line represents the overall bias of +0.08 log 10 copies/mL, and the solid lines indicate ± 2 SD from the mean bias.
❚Figure 1❚ Cytomegalovirus (CMV) linearity plot for diluted CMV AD-169 viral supernatant for EZ1 and QIAsymphony extracted material. Solid lines border the area indicating results within ± 0.3 log 10 copies/mL from the expected value.
Comparison With CMV Antigenemia
Both extraction methods showed increased sensitivity over direct CMV antigen detection in peripheral blood neutrophils. Viral DNA was detected in 12% of EZ1-extracted samples and 21% of QIAsymphony-extracted samples that were negative by CMV antigen testing. CMV was not detected by PCR in 2% of EZ1-extracted samples and 3% of QIAsymphony-extracted samples that were positive for the CMV antigen. In each case, there was 1 positive cell detected with the CMV antigen. Review of patient records showed that all 3 involved patients had negative CMV antigen results before and after the positive test, indicating the possibility that the CMV antigenemia result was a false-positive. The samples extracted using QIAsymphony had better quantitative agreement with CMV antigenemia results, as all samples with more than 3 cells positive by antigen testing were quantified with viral loads above 3.0 log 10 copies/mL by PCR ❚Table 1❚. In comparison, 3 of 41 samples extracted on the EZ1 instrument with CMV antigenemia showing more than 5 positive cells had viral loads less than 3.0 log 10 copies/mL by PCR analysis ❚Table 2❚.
Discussion
Quantification of CMV viral load in peripheral blood is a well-established tool for monitoring the risk of developing CMV disease in solid organ and hematopoietic stem cell transplant recipients, but significant method-specific differences limit the effectiveness of universal practice guidelines and therapeutic decision limits. In a recent comparison of 33 laboratories, only 57.5% of results fell within 0.5 log 10 copies/ mL of expected values, which was thought to be an acceptable range. 8 Development of a universal reference standard would enable laboratories to directly compare various assays and provide interpretation of their results relative to an accepted consensus value, but this material is not yet available. 9 Several variables in testing methods make direct comparisons difficult, including sample type (plasma, whole blood, leukocytes), nucleic acid purification (lysis, purification technique, elution), reagents used (primers, probes, enzymes, buffer), and amplification and detection instruments. Laboratorydeveloped tests may use unique combinations of each of these variables, while more recently developed commercial analyte-specific reagents and kits use a set combination of PCR reagents and detection chemistries. Assuming that a single specimen type is used, the major differences between assays are described by the reagent kit, extraction protocol, and real-time PCR instrument used. Most studies describe comparisons of assays that differ by combinations of 2 or 3 of these major variables, making it difficult to identify specific sources of bias. In particular, the nucleic extraction method has been relatively understudied as a potential source of assay variability.
Our results demonstrate generally good agreement between 2 automated extraction systems using similar chemistries but with subtle differences that could impact clinical interpretation. The EZ1 method was somewhat less sensitive than the QIAsymphony, requiring 0.34 log 10 copies/mL additional virus for detection of 95% of positive samples. In addition, QIAsymphony-extracted specimens were more often positive for CMV than EZ1 extracted samples (21% vs 12%) when compared with CMV pp65 antigenemia, possibly owing to the larger sample input volume of the QIAsymphony. Overall correlation showed that each extraction method yielded results within 0.5 log 10 copies/mL of the average value for all patient specimens tested with a slight positive bias for EZ1-extracted specimens that appeared more pronounced for samples with viral loads less than 4.0 log 10 copies/mL.
The clinical significance of these differences in test characteristics for each nucleic acid extraction method is not completely clear because there are no universal criteria for CMV viral load interpretation, although some authors have attempted to provide guidelines. 10, 11 It is generally accepted that numeric values and limits of detection do not correlate well between various assay methods, although linearity and precision are acceptable. Therefore, clinicians are advised to compare viral loads over time using the same laboratory assay and determine trends that warrant treatment changes, such as increasing titers. At the same time, a single high value would be of concern in a patient at high risk for development of CMV disease, such as a recent bone marrow transplant recipient. In these cases, a decision to immediately treat could be warranted while waiting to establish a trend in CMV viral load. Each of these clinical scenarios requires an answer to the questions "What change in viral titer is considered significant?" and "What level of viremia is concerning in a high-risk patient?" At present, there is no definitive answer to these questions, but reasonable responses can be given based on experience and knowledge of each PCR assay's attributes along with the patient's clinical manifestations. An analytically significant difference in viral load would be a change greater than 2 SD as determined through precision experiments. For our assay, this would require a change of approximately 0.3 log 10 copies/mL, regardless of the extraction method used. When considering clinical variation, a change in titer greater than 0.5 log 10 copies/mL would likely represent a significant change, as suggested by Pang and colleagues. 8 For this reason, a goal to harmonize various methods to within 0.5 log 10 copies/mL of expected reference values would likely be adequate for interlaboratory comparisons of results for clinical purposes. Current CMV PCR assay comparisons show that this goal is not near being met. 4 Our results demonstrate that a change in methods of nucleic acid extraction, using similar chemistry, can meet this goal when applied to a single amplification and detection technique.
There are limitations to both extraction methods studied here that should be considered by laboratories before their implementation. The QIAsymphony method used here requires 1 mL of patient plasma, which can be difficult to obtain from pediatric patients with acute manifestations of leukemia who also require many other tests before transplantation. The QIAsymphony instrument is more suited to high-volume laboratories because it takes more time to set up but can extract more specimens in a batch than can the EZ1 machine.
Significant levels of CMV viremia have been difficult to define because of assay variability between studies and differences in patient characteristics, such as endogenous and exogenous immunosuppression, previous antiviral therapy, evidence of end-organ disease, and comorbid conditions. A single numeric value for viremia is unlikely to provide a treatment threshold that will apply to all patients. Several studies have correlated pp65 antigenemia with PCR detection of CMV and proposed actionable levels of viremia based on their patient population of interest. 12, 13 In a similar vein, common practice at our institution has been to consider any detectable antigenemia clinically significant in a highly immunosuppressed hematopoietic stem cell transplant recipient and trigger treatment of infection, whereas a solid organ transplant recipient might be treated only for antigenemia levels of more than 5 cells per 200,000 cells. Therefore, using QIAsymphony-extracted material would provide a reliable indicator for more than 5 cells by antigenemia when the viral load is greater than 3.0 log 10 copies/ mL, whereas EZ1-extracted specimens would not provide this assurance. Conversely, both extraction methods are considerably more sensitive than CMV antigen detection and will provide for earlier detection of infection, allowing for earlier treatment or increased frequency of monitoring with potential clinical benefit.
Once CMV viremia has been detected, it may be present for prolonged periods, with low-level viremia that can confuse treatment decisions. Eradication of virus from the bloodstream may not be possible for some patients, so the length of treatment should not be based on detection of CMV alone, but in conjunction with other clinical factors. 14 More data will be needed to determine optimal treatment lengths and regimens for the various patient populations currently monitored for development of CMV disease by quantitative PCR.
